German court rules that gilead's sofosbuvir infringes nucana's ‘190 patent

Edinburgh, united kingdom, july 11, 2022 (globe newswire) -- nucana plc (nasdaq: ncna) announced that, following a comprehensive hearing on may 17, 2022, the regional court of dusseldorf (the “court”) issued a judgement on july 7, 2022 that gilead sciences ireland uc and gilead sciences gmbh (together, “gilead”) infringe nucana's composition of matter claims in european patent 2955190 (the “'190 patent”) through their sales of sovaldi®, harvoni®, vosevi® and epclusa® in germany.
NCNA Ratings Summary
NCNA Quant Ranking